Recently, Anson et al. published a RWD study utilizing the TriNetX platform of multimodal pharmacotherapy of a combination of metformin, pioglitazone, sodium-glucose-linked-cotransporter-2 inhibitor (SGLT2i), and glucagon-like peptide-1 receptor agonist (GLP-1RA) versus a more conventional glucocentric treatment (insulin and sulphonylureas) for cardiovascular outcomes in the treatment of type 2 diabetes (Anson et al., 2024a). Here, GLP1R is linked to type 2 diabetes mellitus.